98 related articles for article (PubMed ID: 24236705)
1. Role of patent analysis in corporate R&D.
Barcelon Yang C
Pharm Pat Anal; 2012 Mar; 1(1):5-7. PubMed ID: 24236705
[No Abstract] [Full Text] [Related]
2. Biobusiness on campus: commercialization of university-developed biomedical technologies.
Dueker KS
Food Drug Law J; 1997; 52(4):453-509. PubMed ID: 10346675
[No Abstract] [Full Text] [Related]
3. [Patent research as a way to ensure competitiveness of an object of economic activities].
Horban' IeM; Zhdanova NM
Lik Sprava; 2002; (5-6):3-5. PubMed ID: 12442506
[TBL] [Abstract][Full Text] [Related]
4. Taking knowledge from bench to bank.
Horton B; Wickware P; Gershon D; Gavaghan H
Nature; 1998 Sep; 395(6700):409-14. PubMed ID: 9759734
[No Abstract] [Full Text] [Related]
5. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
6. Japan's innovators take patent deals to court.
Cyranoski D
Nature; 2002 Oct; 419(6908):657. PubMed ID: 12384663
[No Abstract] [Full Text] [Related]
7. The university-promoted patent at the crossroads of the research results and immediate industrial use.
Doddoli R
Biomol Eng; 2007 Feb; 24(1):43-6. PubMed ID: 16890015
[TBL] [Abstract][Full Text] [Related]
8. Color as a trademark under the Lanham Act: confusion in the circuits and the need for uniformity.
Carraway JC
Law Contemp Probl; 1994; 57(4):243-79. PubMed ID: 10140661
[No Abstract] [Full Text] [Related]
9. The changing face of industry.
Cyranoski D
Nature; 2015 Dec; 528(7582):S184-6. PubMed ID: 26673026
[No Abstract] [Full Text] [Related]
10. Technology transfer at US universities: seeking public benefit from the results of basic research.
Goodwin CD
Technol Health Care; 1996 Sep; 4(3):323-30. PubMed ID: 8931243
[TBL] [Abstract][Full Text] [Related]
11. Patent nonsense: evidence tells of an industry out of social control.
Mintzberg H
CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
[No Abstract] [Full Text] [Related]
12. Optimizing patent strategies. Maintain a competitive edge by creating a strategic patent portfolio.
Dykeman DJ
Health Manag Technol; 2011 May; 32(5):26. PubMed ID: 21650138
[No Abstract] [Full Text] [Related]
13. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
14. Biotech industry considers foreign competition measure.
Margolis RE
Healthspan; 1990 Nov; 7(10):19-20. PubMed ID: 10107734
[No Abstract] [Full Text] [Related]
15. Patents and the research exemption.
Resnik DB
Science; 2003 Feb; 299(5608):821-2. PubMed ID: 12574602
[No Abstract] [Full Text] [Related]
16. Will the nanomedicine "patent land grab" thwart commercialization?
Bawa R
Nanomedicine; 2005 Dec; 1(4):346-50. PubMed ID: 17292108
[No Abstract] [Full Text] [Related]
17. Federally funded stem cell research: a good deal for the taxpayer and consumer.
Resnikoff DA
Loyola Consum Law Rev; 2001; 14(1):36-56. PubMed ID: 15977330
[No Abstract] [Full Text] [Related]
18. Protecting rights to early-stage technology.
Shuster MJ; Su H; Blaug S
Nat Biotechnol; 2003 Jun; 21(6):701-3. PubMed ID: 12776151
[No Abstract] [Full Text] [Related]
19. Reexamining the research exemption.
Flores MA; Campbell C
Nat Biotechnol; 2005 Jun; 23(6):659-61. PubMed ID: 15940230
[No Abstract] [Full Text] [Related]
20. Enbrel patent surfaces.
Harrison C
Nat Biotechnol; 2012 Feb; 30(2):123. PubMed ID: 22318016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
